Monoclonal Antibody Contract with Pakistan

BPO Health is proud to announce that we through our competence facilitated and supported the Pakistani team, for the signing of a multi-million Euro contract with Celltrion, for the delivery of their monoclonal antibody drug CT-P59.

In early April BPO Health sat long side with the Pakistani commercial and medical team, to negotiate a deal for purchasing of the monoclonal antibody drug CT-P59 – for use in Pakistan. The country has handled the COVID-19 pandemic remarkably good. In fact, Pakistan is rated as among top three countries in how the government has handled the pandemic. Hong Kong was rated as number one and New Zeeland as number two.

Pakistan wants to continue their excellent work in handling COVID-19 and is thus expanding their toolbox with cutting edge treatments like monoclonal antibodies. BPO Health contributed, among other things, with:

• Overall medical framework for use of monoclonal antibodies

• Contract drafting consulting and advisory service

• Provide legal and regulatory advisory service

• Access to native speaking Pakistani person, for discussions with the Buyer

• Logistics assistance service

BPO Health is proud to be a vital part in this deal, and it proves once more our real capabilities in delivering true values for our clients.